Article Figures & Data
Tables
Radiopharmaceutical Radiation dose to the breast (mGy/MBq [rad/mCi]) Organ receiving largest radiation dose (mGy/MBq [rad/mCi]) Effective dose (mSv/MBq [rem/mCi]) 99mTc-sestamibi, resting subject 0.0038 (0.014) Gallbladder: 0.039 (0.14) 0.0071* to 0.0090 (0.026–0.033) 99mTc-tetrofosmin, resting subject 0.0020 (0.0074) Gallbladder: 0.036 (0.13) 0.0062* to 0.0080 (0.023–0.030) Unless otherwise noted, data are from ICRP Publication 128 (55).
* An updated estimate of effective dose specific to female subjects was provided in Andersson et al. (56).
Fetal dose Stage of gestation mGy/MBq rad/mCi Early 0.015 0.055 3 mo 0.012 0.044 6 mo 0.0084 0.031 9 mo 0.0054 0.020 ↵99mTc-sestamibi dose estimates to fetus are from Russell et al. (57). No information about possible placental crossover of this compound was available for use in estimating fetal doses.
In this issue
Jump to section
- Article
- PREAMBLE
- I. INTRODUCTION
- II. GOALS
- III. COMMON CLINICAL INDICATIONS
- IV. CONTRAINDICATIONS
- V. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
- VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
- VII. DOCUMENTATION/REPORTING
- VIII. EQUIPMENT SPECIFICATIONS
- IX. QUALITY CONTROL
- X. PATIENT EDUCATION
- XI. RADIATION SAFETY
- XII. APPROVAL
- XIII. LIABILITY STATEMENT
- XIV. ACKNOWLEDGMENTS
- XV. REFERENCES
- Figures & Data
- Info & Metrics